November 2026: Innovation Science Issue

As the dietary supplement industry confronts sweeping regulatory reform alongside a surge of frontier science, the innovation landscape reveals sharp tension—breakthrough categories like peptides race ahead of the rules meant to govern them, while bioavailability and clinical rigor emerge as the new battlegrounds for consumer trust. In this issue, NBJ examines the U.S. fight over GRAS reform, NDI pathways, and state-level regulation, the peptide boom fueled by GLP-1 drugs, and how delivery technologies and upcycled ingredients are being validated through real clinical data. Featuring expert perspectives on trial design, ingredient science, and recent legacy brand M&A, the Innovation Science Issue reveals which scientific approaches and regulatory outcomes will define the industry's next phase of growth.

Who it's for: Regulatory and legal counsel, R&D leaders, ingredient suppliers, brand executives, and investors tracking where supplement innovation is heading.

What they'll learn: How GRAS, NDI, and state regulatory changes could reshape ingredient access, where peptides create risk and opportunity, which delivery technologies are gaining real clinical support, how upcycled ingredients are becoming core innovation strategy, and what recent M&A activity signals for the industry.